Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...

Driven by a surging pipeline, the MASH therapeutic landscape is radically transforming as more drugs reach clinical trials. While Madrigal's Rezdiffra marked a groundbreaking first approval, it also ...

The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...

Just 10 months since it launched, The Cruise Globe is targeting half a million users by the end of next year. It calls itself the world’s first free-to-use digital platform that enables travellers to ...

Editors and writers independently select products unless marked Sponsored or Promoted. Sponsored content is a paid ad, while content marked Promoted is chosen by Ziff Davis leadership. We may earn an ...

The unlikely friendship of a boy, a mole, a fox and a horse traveling together in the boy's search for home.